PTC CLINIC
Informace pro odborníky

Reference

1. Pinnix, C., Gunther, J., Fang, P., Bankston, M., Milgrom, S., Boyce, D., Lee, H., Nair, R., Steiner, R., Strati, P., Ahmed, S., Iyer, S., Westin, J., Parmar, S., Rodriguez, M., Nastoupil, L., Neelapu, S., Flowers, C., Dabaja, B. Assessment of Radiation Doses Delivered to Organs at Risk 
2. Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020, 3(9), e2013935. doi:10.1001/jamanetworkopen.2020.13935
3. Travis, L., Hill, D., Dores, G., Gospodarowicz, M., van Leeuwen, F., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C., Van’t Veer, M., Glimelius, I., Storm, H., Pukkala, E., Stovall, M., Curtis, R., Boice, J., Gilbert, E.. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003, 290(4), 465-75. Erratum in: JAMA. 2003 Sep 10;290(10):1318.
4. Kumar, A., Casulo, C., Advani, R., Budde, E., Barr, P., Batlevi, C., Caron, P., Constine, L., Dandapani, S., Drill, E., Drullinsky, P., Friedberg, J., Grieve, C., Hamilton, A., Hamlin, P., Hoppe, R., Horwitz, S., Joseph, A., Khan, N., Laraque, L., Matasar, M., Moskowitz, A., Noy, A., Palomba, M., Schoder, H., Straus, D., Vemuri, S., Yang, J., Younes, A., Zelenetz, A., Yahalom, J., Moskowitz, C.. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021, 39(20), 2257-2265. doi.org/10.1200/JCO.21.00108
5. van Nimwegen, F., Schaapveld, M., Janus, C., Krol, A., Petersen, E., Raemaekers, J., Kok, W., Aleman, B., van Leeuwen, F.. Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk. JAMA Intern Med. 2015, 175(6), 1007-17.
6. Galper, S., Yu, J., Mauch, P., Strasser, J., Silver, B., LaCasce, A., Marcus, K., Stevenson, M., Chen, M., Ng, A. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011, 117(2), 412-8. DOI 10.1182/blood-2010-
   06-291328.
7. Hoppe, B., Hill-Kayser, C., Tseng, Y., Flampouri, S., Elmongy, H., Cahlon, O., Mendenhall, N., Maity, A., McGee, L., Plastaras, J. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma Annals of Oncology [online]. 2017, 2017-09-01, 28(9), 2179-2184 [cit. 2018-10-26]. ISSN 0923-7534.
8. Loap, P., Mirandola, A., De Marzi, L., Dendale, R., Iannalfi, A., Vitolo, V., Barcellini, A., Filippi, A., Jereczek-Fossa, B., Kirova, Y., Orlandi, E.. Current Situation of Proton Therapy for Hodgkin Lymphoma From Expectations to Evidence. Cancers (Basel). 2021, 13(15), 3746. doi.org/10.3390/cancers13153746
9. André, M., Carde, P., Viviani, S., Bellei, M., Fortpied, C., Hutchings, M., Gianni, A., Brice, P., Casasnovas, O., Gobbi, P., Zinzani, P., Dupuis, J., Iannitto, E., Rambaldi, A., Brière, J., Clément-Filliatre, L., Heczko, M., Valagussa, P., Douxfils, J., Depaus, J., Federico, M., Mounier, N.. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma A pooled analysis of four randomized trials Cancer Med. 2020, 9(18), 6565–6575. DOI: 10.1002/cam4.3298
10. Fuchs, M., Goergen, H., Kobe, C., Kuhnert, G., Lohri, A., Greil, R., Sasse, S., Topp, M., Schafer, E., Hertenstein, B., Soekler, M., Vogelhuber, M., Zijlstra, J., Keller, U., Krause, S., Wilhelm, M., Maschmeyer, G., Thiemer, J., Duhrsen, U., Meissner, J., Viardot, A., Eich, H., Baues, C., Diehl, V., Rosenwald, A., von Tresckow, B., Dietlein, M., Borchmann, P., Engert, A.. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019, 37(31), 2835-2845. doi.org/10.1200/JCO.19.00964
11. Pei, F., Yu, Y., Dong, B., Guan, H., Dong, X., Zhao, F.. Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma. Front. Pharmacol. 2021, 12. doi: 10.3389/fphar.2021.694545
12. André, M., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., Edeline, V., Fermé, C., van Imhoff, G., Merli, F., Bouabdallah, R., Sebban, C., Specht, L., Stamatoullas, A., Delarue, R., Fiaccadori, V., Bellei, M., Raveloarivahy, T., Versari, A., Hutchings, M., Meignan, M., Raemaekers, J. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma Final Results of the Randomized EORTCLYSAFIL H10 Trial. J Clin Oncol. 2017, 35(16), 1786-1794. doi.org/10.1200/JCO.2016.68.6394
13. Houlihan, O., Ntentas, G., Cutter, D., Daly, P., Gillham, C., McArdle, O., Duane, F.. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma. Clin Transl Oncol. 2022.
14. Aleman, B., van den Belt-Dusebout, A., De Bruin, M., van ’t Veer, M., Baaijens, M., de Boer, J., Hart, A., Klokman, W., Kuenen, M., Ouwens, G., Bartelink, H., van Leeuwen, F. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood [online]. 2007, 109(5), 1878-86 [cit. 2023-09-01]. DOI 10.1182/blood-2006-07-034405.
15. Zeng, C., Plastaras, J., James, P., Tochner, Z., Hill-Kayser, C., Hahn, S., Both, S.. Proton pencil beam scanning for mediastinal lymphoma treatment planning and robustness assessment. Acta Oncologica [online]. 2016, 2016-06-22, 55(9-10), 1132-1138 [cit. 2018-10-26]. ISSN 0284-186X. DOI: 10.1080/0284186X.2016.1191665
16. Baron, J., Wright, C., Maxwell, R., Kim, M., Giap, F., Mailhot Vega, R., Hoppe, B., LaRiviere, M., Maity, A., Plastaras, J., Paydar, I.. Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration. Adv Radiat Oncol. 2022, 8(1), 101090. doi.org/10.1016/j.adro.2022.101090
17. Baues, C., Marnitz, S., Engert, A., Baus, W., Jablonska, K., Fogliata, A., Vásquez-Torres, A., Scorsetti, M., Cozzi, L. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation a planning comparison of deep inspiration breath hold intensity modulation radiotherapy and intensity modulated proton therapy. Radiat Oncol. 2018, 13(1), 122. Baues et al. Radiation Oncology (2018) 13:122. doi.org/10.1186/s13014-018-1066-2
18. Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., McMillan, A., Brownell, A., Kruger, A., Lister, A., Hoskin, P., O’Doherty, M., Barrington, S.. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015, 372(17), 1598-607. DOI: 10.1056/NEJMoa1408648
19. Franklin, J., Pluetschow, A., Paus, M., Specht, L., Anselmo, A., Aviles, A., Biti, G., Bogatyreva, T., Bonadonna, G., Brillant, C., Cavalieri, E., Diehl, V., Eghbali, H., Fermé, C., Henry-Amar, M., Hoppe, R., Howard, S., Meyer, R., Niedzwiecki, D., Pavlovsky, S., Radford, J., Raemaekers, J., Ryder, D., Schiller, P., Shakhtarina, S., Valagussa, P., Wilimas, J., Yahalom, J.. Second malignancy risk associated with treatment of Hodgkin’s lymphoma meta-analysis of the randomised trials. Ann Oncol. 2006, 17(12), 1749-60. doi:10.1093/annonc/mdl302
20. Ng, A. K., Bernardo, M. V. P., Weller, E., Backstrand, K., Silver, B., Marcus, K. C., Tarbell, N. J., Stevenson, M. A., Friedberg, J. W., Mauch, P. M.. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy long-term risks and risk factors. Blood. 2002, 100(6), 1989-96.
21. König, L., Haering, P., Lang, C., Splinter, M., von Nettelbladt, B., Weykamp, F., Hoegen, P., Lischalk, J. W., Herfarth, K., Debus, J., Hörner-Rieber, J.. Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Front Oncol. 2020, 10, 989. doi: 10.3389/fonc.2020.00989
22. Loap P, Mirandola A, De Marzi L, Dendale R, Iannalfi A, Vitolo V, Barcellini A, Filippi AR, Jereczek-Fossa BA, Kirova Y, Orlandi E. Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence. Cancers (Basel). 2021 Jul 26;13(15):3746. doi: 10.3390/cancers13153746. PMID: 34359647; PMCID: PMC8345146.
23. Loap P, De Marzi L, Mirandola A, Dendale R, Iannalfi A, Vitolo V, Barcellini A, Filippi AR, Jereczek-Fossa BA, Kirova Y, Orlandi E. Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives.Cancers (Basel). 2021 Jul 26;13(15):3744. doi: 10.3390/cancers13153744. PMID: 34359644; PMCID: PMC8345082.
24. Tringale KR, Modlin LA, Sine K, Forlenza CJ, Cahlon O, Wolden SL. Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients.Radiother Oncol. 2022 Mar;168:46-52. doi: 10.1016/j.radonc.2022.01.016. Epub 2022 Jan 29. PMID: 35101461; PMCID: PMC9446376
25. Patel CG, Peterson J, Aznar M, Tseng YD, Lester S, Pafundi D, Flampouri S, Mohindra P, Parikh RR, Mailhot Vega R, Konig L, Plastaras JP, Bates JE, Loap P, Kirova YM, Orlandi E, Lütgendorf-Caucig C, Ntentas G, Hoppe B. Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: A PTCOG Lymphoma Subcommittee report and recommendations. Radiother Oncol. 2022 Dec;177:21-32. doi: 10.1016/j.radonc.2022.10.003. Epub 2022 Oct 14. PMID: 36252635.
26. Tseng YD, Pankuch M, Mohindra P, McGee L, Rossi C, Flampouri S, Hajj C, Molitoris JK, Chang JH, Tsai H, Stevens C, Rosen L, Vargas C, Hartsell W. Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines. Am J Clin Oncol. 2021 Jun 1;44(6):269-274. doi: 10.1097/COC.0000000000000819. PMID: 33852456.
27. Loap P, Orlandi E, De Marzi L, Vitolo V, Barcellini A, Iannalfi A, Dendale R, Kirova Y, Mirandola A. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy. Acta Oncol. 2022 Aug;61(8):979-986. doi: 10.1080/0284186X.2022.2084639. Epub 2022 Jun 6. PMID: 35668710.
28. Buglione M, Guerini AE, Filippi AR, Spiazzi L, Pasinetti N, Magli A, Toraci C, Borghetti P, Triggiani L, Alghisi A, Costantino G, Bertagna F, Giaj Levra N, Pegurri L, Magrini SM. A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin’s Lymphoma. Crit Rev Oncol Hematol. 2021 Nov;167:103437. doi: 10.1016/j.critrevonc.2021.103437. Epub 2021 Aug 3. PMID: 34358649.
29. Dionisi F, Scartoni D, Rombi B, Vennarini S, Righetto R, Farace P, Lorentini S, Schwarz M, Di Murro L, Demofonti C, D’Angelillo RM, Petrongari MG, Sanguineti G, Amichetti M. Consolidative active scanning proton therapy for mediastinal lymphoma: selection criteria, treatment implementation and clinical feasibility. Strahlenther Onkol. 2022 Jun;198(6):558-565. doi: 10.1007/s00066-022-01918-1. Epub 2022 Apr 8. PMID: 35394144.
30. O’steen L, Bellardini J, Cury J, Jones L, Seeram VK, Mendenhall NP, Hoppe BS. Pulmonary Function after Proton Therapy for Hodgkin Lymphoma.Int J Part Ther. 2019 Winter;5(3):1-4. doi: 10.14338/IJPT-18-00040.1. Epub 2019 Mar 21. PMID: 31788502; PMCID: PMC6874186.
31. Rosenbrock J, Baues C, Vasquez-Torres A, Clivio A, Fogliata A, Borchmann P, Marnitz S, Cozzi L. Volumetric modulated arc therapy versus intensity-modulated proton therapy in the irradiation of infra diaphragmatic Hodgkin Lymphoma in female patients. Acta Oncol. 2022 Jan;61(1):81-88. doi: 10.1080/0284186X.2021.1986230. Epub 2021 Oct 1. PMID: 34596491.
32. Bates JE, Terezakis S, Morris CG, Rao AD, Sehgal S, Kumar R, Mailhot Vega RB, Mendenhall NP, Hoppe BS. Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin LymphomaInt J Part Ther. 2021 Jul 8;8(3):21-27. doi: 10.14338/IJPT-21-00011.1. PMID: 35127972; PMCID: PMC8768899.

Reference CAR-T

1. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016 Jan;51(1):51-7. doi: 10.1038/bmt.2015.213. Epub 2015 Sep 14. PMID: 26367239.
2. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1;131(5):587-588. doi: 10.1182/blood-2017-11-817775. PMID: 28774879; PMCID: PMC5649550.)
3. Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct 20;42(30):3581-3592. doi: 10.1200/JCO.23.02786. Epub 2024 Aug 2. PMID: 39094076; PMCID: PMC11483191.) Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct 20;42(30):3581-3592. doi: 10.1200/JCO.23.02786. Epub 2024 Aug 2. PMID: 39094076; PMCID: PMC11483191.)
4. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020 Jul 14;4(13):2871-2883. doi: 10.1182/bloodadvances.2020001837. PMID: 32589728; PMCID: PMC7362355.)
5. Fan J, Adams A, Sieg N, Heger JM, Gödel P, Kutsch N, Kaul D, Teichert M, von Tresckow B, Bücklein V, Goesmann G, Li M, Struve N, Trommer M, Linde P, Rosenbrock J, Celik E, Penack O, Stuschke M, Subklewe M, Belka C, von Bergwelt-Baildon M, Borchmann P, Marnitz S, Baues C. Potential synergy between radiotherapy and CAR T-cells – a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy. Radiother Oncol. 2023 Jun;183:109580. doi: 10.1016/j.radonc.2023.109580. Epub 2023 Feb 25. PMID: 36842663.
6. Guerini AE, Filippi AR, Tucci A, Simontacchi G, Re A, Guaineri A, Morelli V, Borghetti P, Triggiani L, Pegurri L, Pedretti S, Volpi G, Spiazzi L, Magrini SM, Buglione M. ‚Le Roi est mort, vive le Roi‘: New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy. Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):e135-e148. doi: 10.1016/j.clml.2021.09.005. Epub 2021 Sep 10. PMID: 34728169
7. Manzar GS, Wu SY, Dudzinski SO, Cha EE, Yoder AK, Corrigan KL, Nasr LF, Sallard G, Ahmed S, Fayad LE, Chihara D, Nair R, Westin JR, Daher M, Neelapu SS, Nastoupil LJ, Gunther JR, Pinnix CC, Dabaja BS, Strati P, Fang PQ. Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy. Int J Radiat Oncol Biol Phys. 2024 Sep 19:S0360-3016(24)03394-7. doi: 10.1016/j.ijrobp.2024.09.023. Epub ahead of print. PMID: 39303997.
8. de Boer JW, Pennings ERA, Kleinjan A, van Doesum JA, Spanjaart AM, Mutsaers PGNJ, Jak M, van der Poel MWM, Kuipers MT, Adam JA, Diepstra A, Koens L, van Dorp S, Vermaat JSP, Niezink AGH, Kersten MJ, van Meerten T. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy. Blood Adv. 2023 Nov 14;7(21):6710-6716. doi: 10.1182/bloodadvances.2023010665. PMID: 37639324; PMCID: PMC10641469.

Klinické studie – účast PTC

1. IESLG 37 – Role konsolidační RT u pacientů s primárním mediastinálním B-lymfomem. Interní hematologická klinika FN Královské Vinohrady, Onkologická klinika 2. LF UK a Fakultní nemocnice Motol (zajištění moderní fotonové RT – technika IMRT, VMAT)
2. Dose – Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma – Fáze II studie Konsolidační radioterapie s redukcí dávky u pacientů  s difuzním velkobuněčným B- lymfomem. Mezinárodní studie DLBCL – ILROG Paris Research Collaboration – Phase II DLBCL Study vedena DUKE Cancer Institute, Department of Radiology. Účast společně s FN Motol.
3. Impact of DHL/THL on RT efficacy for r/r DLBCL patients – ILROG collaborative study. Účast ve studii ILROG s DHL/THL DLBCL, studii vede University of Washington, Dr. Yolanda Tseng.
4. An Excess Mortality Risk Analysis of Proton Beam versus Optimal Proton Radiotherapy for Mediastinal Hodgkin  Lymphoma: Who May Benefit Most? – Modelová studie s Nuffield Dpt. University of Oxford + St. Guy´s Hospital – pokračující spolupráce, analýza souboru pacientů PTC.
5. EuroNet – PHL – C2 – ve spolupráci s FN Motol, studie vedena Prof. Karin Dieckmann, AKH Wien.

Tuzemské zdroje informací

1. www.hodgkin.cz  odborná veřejnost i pacienti, komplexní informace o Hodgkinově lymfomu pro lékaře i pacienty, brožura a poradna pro pacienty.
2. www.lymphoma.cz odborná veřejnost i pacienti, komplexní informace týkající se problematiky Hodgkinova I non-Hodgkinova lymfomu, k dispozici aktuální doporučení pro diagnostiku a léčbu lymfomů včetně RT.
3. www.lymfomhelp.cz pacienti, komplexní informace a pomoc pro pacienty před, v léčbě či po léčbě lymfomu.
4. www.linkos.cz odborná veřejnost i pacienti, stránky České onkologické společnosti.
5. www.srobf.cz  odborná veřejnost, stránky Společnosti radiační onkologie, biologie a fyziky.
6. https://www.amelie-zs.cz/ Projekt psychosociální pomoci, pro pacienty s nádorovým onemocněním.

Zahraniční zdroje informací

1. www.nccn.org odborná veřejnost i pacienti, doporučení (guidelines) pro jednotlivé typy zhoubných nádorů včetně doporučených technik ozáření.
2. https://www.ptcog.ch/index.php/other-ptcog-sub-committees?id=53  odborná veřejnost, informace o publikacích týkající se protonové RT lymfomů.
3. www.ilrog.com odborná veřejnost, informace o postavení a provedení radioterapie u lymfomů.
4. www.ihaddcancer.com projekt svépomoci a sdílení zkušeností pacientů, kteří se léčili nebo léčí s rakovinou.

Videa k protonové RT lymfomů (anglicky)

1. https://www.youtube.com/watch?v=prh-5CQ3nsY, dr. Gomez, Proton Therapy Treatment for Lymphoma, MD Anderson Proton Therapy Center.
2. https://www.youtube.com/watch?v=NNLoQSaAuzA , dr.Hoppe, Proton Therapy for Lymphoma, University of Florida Proton Therapy Institute.
3. https://www.youtube.com/watch?v=VlKlPuKrSSw, dr.Dabaja, Proton and photon therapy in managing hematological malignancies, MD Anderson Cancer Center, Houston, TX